Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03150810
Title Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BeiGene

triple-receptor negative breast cancer

lung small cell carcinoma

stomach cancer

ovarian cancer

Advanced Solid Tumor

prostate cancer


Pamiparib + Temozolomide

Age Groups: senior | adult
Covered Countries USA | ESP

No variant requirements are available.